Bristol-Myers Squibb Australia
GPTKB entity
Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Celgene_Corporation
|
| gptkbp:awards |
innovation awards
best workplace awards |
| gptkbp:clinicalTrials |
data analysis
regulatory compliance patient recruitment safety monitoring ongoing studies efficacy studies phase 1 trials phase 2 trials phase 3 trials completed studies |
| gptkbp:collaborations |
academic institutions
biotech companies |
| gptkbp:communityEngagement |
health awareness campaigns
patient support programs |
| gptkbp:culturalHeritage |
diversity and inclusion
team collaboration work-life balance employee development innovation focus |
| gptkbp:employees |
approximately 1,000
|
| gptkbp:financialPerformance |
market share
revenue growth investment in R&D profit_margins |
| gptkbp:focusArea |
oncology
fibrosis cardiovascular diseases immunology |
| gptkbp:founded |
1887
|
| gptkbp:headquarters |
gptkb:Sydney
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bristol-Myers Squibb Australia
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:leadership |
CEO
executive team |
| gptkbp:market |
gptkb:Australia
gptkb:New_Zealand |
| gptkbp:operatesIn |
gptkb:Australia
|
| gptkbp:parentCompany |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:partnerships |
research institutions
healthcare_providers |
| gptkbp:products |
cancer treatments
cardiovascular drugs immunotherapy drugs |
| gptkbp:regulatoryCompliance |
FDA_approval
TGA_approval |
| gptkbp:researchAndDevelopment |
clinical trials
|
| gptkbp:sustainabilityInitiatives |
ethical sourcing
community investment environmental responsibility |
| gptkbp:website |
www.bms.com.au
|